File: Attachment 06182469-00000001-00022463-20240909_-_Ventripoint_2-PDF.pdf

Ventripoint to Launch Reference Site Programme to Deepen Collaborations With Hospital Partners

For Immediate Release

Toronto, Canada -- September 9, 2024 -- Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTCQB:VPTDF), a leading provider of innovative cardiac diagnostic solutions, is pleased to announce the launch of its new reference site programme. This initiative aims to foster collaboration with key stakeholders in major hospitals to enhance the accuracy, efficiency and diagnostic capabilities of echocardiography.

By engaging with healthcare professionals at the forefront of cardiac care, Ventripoint seeks to continue to gain invaluable insights into the clinical needs and challenges faced in everyday practice. This collaborative approach will enable the company to continuously improve VMS+ to meet the evolving demands of the healthcare landscape and deliver optimal patient outcomes.

Ventripoint is currently in discussions with candidate sites and over the next few months will announce the institutions and further information regarding the scope of these relationships.

The reference site programme will provide participating hospitals with early access to VMS+ technology, expert training, and ongoing support. Ventripoint is committed to working closely with these partners to ensure the successful implementation and utilization of VMS+ within their routine clinical workflows. Partner sites will provide greater local visibility of the capabilities of VMS+ and enable more effective peer-to-peer communication regarding adoption of the technology.

"Working closely with clinical experts has been core to everything we do at Ventripoint since the company's founding at the University of Washington," said Ventripoint's CEO Hugh MacNaught. "The reference site programme brings us closer to renowned centres of cardiac excellence in the United States, Europe, the UK and Canada. It will provide the opportunity for us to expand applications of our technology to new patient groups and demonstrate value-in-use through more timely treatment decisions and improved patient outcomes."

For further information, please contact: Hugh MacNaught President and CEO hmacnaught@ventripoint.com (604) 671-4201

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

Forward Looking Statements This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.